Chinese maker of complex generic and peptide active pharmaceutical ingredients, including antiviral and specialty drug APIs.
Chinese maker of complex generic and peptide active pharmaceutical ingredients, including antiviral and specialty drug APIs.
Moat: narrow (process know-how). Specialized synthesis capability for complex generics and peptide APIs.
Headquarters: Suzhou, China · Employees: 1,196
Size BrightGene Bio-Medical Technology (688166.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.71B, the 1340th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥26.53 on 18 Nov 2026.
Performance Over six months the shares fell 57.5%, against +1.8% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 20 in its peer set.
Growth Revenue grew 13.8% over the last twelve months (peer median +6.6%); the operating margin is 7.1% (peer median 8.6%).
Valuation It trades at 74.9× forward earnings against a peer median of 19.4× (2nd most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 35% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is +26 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 5.9 points below its cost of capital (9.3% WACC).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.34B | CN¥1.22B | CN¥1.28B | CN¥1.18B | CN¥1.02B |
| Revenue growth | — | -5% | +9% | +16% | — |
| Gross profit | CN¥823M | CN¥570M | CN¥695M | CN¥621M | CN¥604M |
| EBITDA | n/a | CN¥204M | CN¥311M | CN¥288M | CN¥292M |
| Net income | CN¥102M | CN¥54.5M | CN¥189M | CN¥202M | CN¥240M |
| Free cash flow | CN¥158M | -CN¥133M | -CN¥25.8M | -CN¥210M | -CN¥372M |
| Capital expenditure | CN¥278M | CN¥453M | CN¥257M | CN¥404M | CN¥727M |
| Total debt | CN¥2.55B | CN¥2.41B | CN¥2.29B | CN¥2.25B | CN¥2.05B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| BrightGene Bio-Medical Technology 688166.SS | $1.71B | -57% | +14% | 7% | 74.9× | 35.3% |
| Hybio Pharmaceutical 300199.SZ | $2.68B | -8% | +70% | 31% | 44.7× | 37.4% |
| Bachem BANB.SW | $7.06B | 0% | +5% | 19% | 32.4× | n/a |
| PolyPeptide PPGN.SW | $1.61B | +7% | +22% | 7% | 52.1× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688166.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -16.3% | -0.3% | 5th lowest of 21 |
| 6-month return | -57.5% | +1.8% | lowest of 20 |
| Distance from 52-week high | -63.6% | -32.1% | lowest of 21 |
| Revenue growth (TTM) | +13.8% | +6.6% | 9th highest of 20 |
| Operating margin | 7.1% | 8.6% | 8th lowest of 20 |
| Forward P/E | 74.9× | 19.4× | 2nd most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 35.3% | 10.1% | most demanding of 16 |
| Growth delivered (Del g) | +9.2% | +8.2% | 8th highest of 16 |
| Hurdle (Req g minus delivered) | +26.1 pp | -0.2 pp | 2nd most demanding of 16 |
| ROIC minus cost of capital | -5.9 pp | -0.8 pp | 7th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| BrightGene Bio-Medical Technology 688166.SS | China | $1.71B | -57% | +14% | 7% | 74.9× | 35.3% | +9.2% |
| Maze Therapeutics MAZE | United States | $1.71B | +27% | -100% | -821% | n/a | n/a | n/a |
| Faes Farma FAE.MC | Spain | $1.71B | +6% | +32% | 14% | 17.4× | 3.7% | +9.9% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.70B | -36% | -28% | -50% | 22.0× | 11.3% | -11.0% |
| NATCO Pharma NATCOPHARM.NS | India | $1.73B | -27% | -30% | 17% | 19.1× | 20.5% | +19.0% |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.70B | +2% | +17% | 31% | 21.4× | 24.3% | +15.7% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.70B | +2% | +7% | 17% | 17.0× | -3.5% | +6.8% |
| Indegene INDGN.NS | India | $1.69B | +28% | +36% | 12% | 29.5× | 31.4% | +29.4% |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.67B | -12% | +7% | 39% | 26.3× | 18.4% | +10.8% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| Agios Pharmaceuticals AGIO | United States | $1.78B | +4% | +214% | -298% | n/a | n/a | n/a |
| Shenzhen Hepalink Pharmaceutical 9989.HK | Hong Kong | $1.78B | -13% | -1% | 8% | 8.7× | -0.4% | -0.2% |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +8% | +15% | 35% | 9.2× | -14.9% | +13.5% |
| Harbin Pharmaceutical 600664.SS | China | $1.78B | +32% | +2% | 5% | 19.7× | -5.3% | +8.2% |
| Eton Pharmaceuticals ETON | United States | $1.79B | +226% | +101% | 29% | 24.6× | 21.9% | +359.6% |
| United Laboratories International 3933.HK | Hong Kong | $1.80B | -20% | -13% | 5% | 13.0× | 1.2% | +7.8% |
| Qingdao Baheal Medical 301015.SZ | China | $1.81B | +2% | -6% | 8% | 21.0× | 10.1% | +5.0% |
| Ultragenyx Pharmaceutical RARE | United States | $1.81B | -24% | +16% | -64% | 9.6× | n/a | n/a |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $1.62B | -47% | -18% | 9% | n/a | 33.0% | +0.9% |
| Zymeworks ZYME | United States | $1.81B | +5% | +98% | 17% | 160.4× | n/a | n/a |
| China National Accord Medicines 000028.SZ | China | $1.81B | -3% | 0% | 2% | 10.8× | -9.5% | +4.2% |